🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

RecruitingPhase 2Ages 18 Years - anyAllPeking Union Medical College Hospital
NCT06454968 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab and lenalidomide in untreated marginal zone lymphoma. The primary objective was the best complete response rate (CRR).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years, either sex. * Histopathologically confirmed B-cell non-Hodgkin lymphoma MZL (splenic, nodal, or extra-nodal). * At least 1 measurable lesion * Eligible for treatment: meets the GELF criteria, or has clinical symptoms/organ dysfunction related to the disease * Patients who are not suitable for local radiotherapy or whose condition progresses after local treatment, and those not suitable for local radiotherapy include the following situations: * Ann Arbor non-continuous Stage II or Stage III-IV non-gastric MALT and nodal MZL * SMZL (Splenic Marginal Zone Lymphoma) * Gastric MALT with Lugano Stage II2/IIE/IV * ECOG performance status (PS) score of 0-2. * Expected survival time is ≥3 months * Sign the Informed consent Exclusion Criteria: * Currently has other malignant tumors; * Lymphoma involving the central nervous system * Allergic to any of the study drugs; * Active infection or uncontrolled HBV infection (DNA\>105/ml), HIV/AIDS, or other severe infectious diseases; * Pregnant or lactating women and women of childbearing age who are unwilling to use contraception; * Any other conditions deemed unsuitable for participation in this trial by the investigator.
💊

What it tests

  • Orelabrutinib, obinutuzumab, lenalidomide
📍

Where

1 site
Peking Union Medical College Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy